阿普司特治疗银屑病及其他疾病：对一种小分子药物寄予厚望
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.
作者信息
Afra T P, Razmi T Muhammed, Dogra Sunil
机构信息
Department of Dermatology, IQRAA International Hospital and Research Centre, Calicut, Kerala, India.
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12. doi: 10.4103/idoj.IDOJ_437_18.
Abstract
Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses. Being a relatively new drug in the treatment armamentarium of psoriasis and other inflammatory dermatoses; in this review, we will discuss various practical aspects of prescribing oral apremilast, based on the current and emerging literature.
摘要
阿普米司特是一种口服的磷酸二酯酶4（PDE4）小分子抑制剂，已获美国食品药品监督管理局批准用于治疗活动性银屑病关节炎（2014年3月21日）和中度至重度斑块状银屑病（2014年9月23日）。2017年，它获得了印度药品总监的批准，可在印度上市。该药物因其良好的安全性和处方便利性，备受皮肤科执业医生关注。最初作为口服小分子药物用于银屑病患者，如今，从近期关于其超说明书用药的文献激增可见，该药物已被用于多种其他适应症。作为银屑病和其他炎症性皮肤病治疗药物库中一种相对较新的药物，在本综述中，我们将基于当前及新出现的文献，讨论口服阿普米司特处方的各个实际方面。
相似文献
1
Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.阿普司特治疗银屑病及其他疾病：对一种小分子药物寄予厚望
Indian Dermatol Online J. 2019 Jan-Feb;10(1):1-12. doi: 10.4103/idoj.IDOJ_437_18.
2
Evolving utility of apremilast in dermatological disorders for off-label indications.阿普司特在皮肤科疾病中的应用不断发展，用于治疗标签外适应证。
Clin Exp Dermatol. 2022 Dec;47(12):2136-2149. doi: 10.1111/ced.15377. Epub 2022 Oct 8.
3
Apremilast: A Review in Psoriasis and Psoriatic Arthritis.阿普米司特：用于银屑病和银屑病关节炎的治疗。
Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1.
4
Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.阿普米拉斯治疗斑块状银屑病：在银屑病中的差异应用
Clin Cosmet Investig Dermatol. 2022 Mar 8;15:395-402. doi: 10.2147/CCID.S266036. eCollection 2022.
5
On- and Off-Label Uses of Apremilast in Dermatology.阿普米司特在皮肤科的适应证内和适应证外使用。
Acta Dermatovenerol Croat. 2020 Dec;28(3):171-179.
6
Drug safety evaluation of apremilast for treating psoriatic arthritis.阿普司特治疗银屑病关节炎的药物安全性评估
Expert Opin Drug Saf. 2015 Jun;14(6):979-85. doi: 10.1517/14740338.2015.1031743. Epub 2015 Mar 31.
7
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.一种用于治疗中度至重度斑块状银屑病的新型疗法：阿普米拉斯。
Expert Rev Clin Immunol. 2016;12(3):237-49. doi: 10.1586/1744666X.2016.1134319.
8
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.阿普司特，一种口服磷酸二酯酶4（PDE4）抑制剂：执业护士治疗银屑病患者的一种新的治疗选择。
J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695. doi: 10.1002/2327-6924.12428. Epub 2016 Nov 21.
9
Safety evaluation of apremilast for the treatment of psoriasis.阿普米司特治疗银屑病的安全性评估。
Expert Opin Drug Saf. 2017 Mar;16(3):381-385. doi: 10.1080/14740338.2017.1288714. Epub 2017 Feb 7.
10
Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.银屑病和银屑病关节炎的治疗进展——阿普米司特的作用
Psoriasis (Auckl). 2015 Sep 7;5:117-124. doi: 10.2147/PTT.S69476. eCollection 2015.
引用本文的文献
1
Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.平衡疗效与肝毒性：银屑病治疗中口服药物的综合综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04334-1.
2
Persistence of advanced systemic pharmacological treatment of moderate-to-severe psoriasis among bio-naïve patients-A retrospective register-based cohort study in Finland and Sweden.初治生物制剂患者中重度银屑病的晚期全身药物治疗持续性——芬兰和瑞典一项基于登记处的回顾性队列研究
J Eur Acad Dermatol Venereol. 2025 Mar;39 Suppl 1(Suppl 1):50-64. doi: 10.1111/jdv.20198. Epub 2024 Aug 2.
3
Fabrication and characterization of apremilast-loaded zinc oxide-mesoporous silica nanoparticles for psoriasis treatment.阿普司特负载氧化锌介孔硅纳米粒的制备及性能评价及其在银屑病治疗中的应用。
Ther Deliv. 2024;15(6):449-462. doi: 10.1080/20415990.2024.2343646. Epub 2024 May 22.
4
An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.头皮银屑病的当代和未来治疗策略概述。
Curr Drug Targets. 2024;25(5):353-373. doi: 10.2174/0113894501292755240304063020.
5
A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis.甲氨蝶呤与甲氨蝶呤联合阿普司特治疗中度至重度慢性斑块状银屑病疗效的比较研究
Indian J Dermatol. 2023 Jul-Aug;68(4):393-398. doi: 10.4103/ijd.ijd_813_22.
6
Psoriasis and its Association with Metabolic Syndrome.银屑病及其与代谢综合征的关联
Indian J Dermatol. 2023 May-Jun;68(3):274-277. doi: 10.4103/ijd.ijd_418_23.
7
Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.口腔小分子酪氨酸激酶 2 和磷酸二酯酶 4 抑制剂治疗斑块状银屑病：网状荟萃分析。
Front Immunol. 2023 Jun 2;14:1180170. doi: 10.3389/fimmu.2023.1180170. eCollection 2023.
8
Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis.阿普米拉斯或甲氨蝶呤：银屑病治疗的利器
Cureus. 2023 May 9;15(5):e38802. doi: 10.7759/cureus.38802. eCollection 2023 May.
9
Evidence of epistasis in regions of long-range linkage disequilibrium across five complex diseases in the UK Biobank and eMERGE datasets.在英国生物银行和 eMERGE 数据集的五个复杂疾病的长程连锁不平衡区域中发现了上位性的证据。
Am J Hum Genet. 2023 Apr 6;110(4):575-591. doi: 10.1016/j.ajhg.2023.03.007.
10
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.大麻素化合物作为治疗非癌症皮肤疾病的一种药物治疗选择。
Cells. 2022 Dec 16;11(24):4102. doi: 10.3390/cells11244102.
本文引用的文献
1
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.阿普司特与生物制剂联合治疗作为银屑病关节炎和银屑病的安全选择
Curr Rheumatol Rev. 2019;15(3):234-237. doi: 10.2174/1573397115666181130094455.
2
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.阿普米司特治疗中重度化脓性汗腺炎的随机对照研究结果。
J Am Acad Dermatol. 2019 Jan;80(1):80-88. doi: 10.1016/j.jaad.2018.06.046. Epub 2018 Jul 3.
3
Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.钙泊三醇倍他米松气雾剂泡沫与阿普米司特、甲氨蝶呤、阿维 A 或富马酸酯治疗斑块状银屑病的比较：匹配调整后的间接比较。
J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1107-1115. doi: 10.1111/jdv.15369. Epub 2019 Mar 19.
4
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.一项评估阿普米司特治疗中重度斑秃患者的安全性和有效性的随机安慰剂对照单中心探索性研究。
Arch Dermatol Res. 2019 Jan;311(1):29-36. doi: 10.1007/s00403-018-1876-y. Epub 2018 Nov 11.
5
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.真实世界中生物制剂初治患者应用阿普司特或生物制剂治疗银屑病的美国医疗成本。
J Comp Eff Res. 2019 Jan;8(1):45-54. doi: 10.2217/cer-2018-0097. Epub 2018 Nov 2.
6
Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.阿普司特作为一名重度银屑病HIV阳性患者的治疗选择。
Dermatol Ther. 2018 Nov;31(6):e12719. doi: 10.1111/dth.12719. Epub 2018 Oct 24.
7
Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.治疗中度斑块型银屑病：接受阿普米司特治疗的患者前瞻性 6 个月图表回顾。
J Dermatolog Treat. 2019 Aug;30(5):430-434. doi: 10.1080/09546634.2018.1528326. Epub 2018 Nov 26.
8
Treatment of Severe Hailey-Hailey Disease With Apremilast.阿普米司特治疗严重 Hailey-Hailey 病。
JAMA Dermatol. 2018 Dec 1;154(12):1453-1456. doi: 10.1001/jamadermatol.2018.2191.
9
Improvement of alopecia areata with apremilast.阿普司特治疗斑秃的疗效观察
Australas J Dermatol. 2019 May;60(2):144-145. doi: 10.1111/ajd.12934. Epub 2018 Oct 7.
10
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.新型疗法治疗中重度斑块型银屑病的长期疗效：PASI 反应的系统评价和网络荟萃分析。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.
Zotero 插件